DNA Repair in Non-Dividing Macrophages Through Reversible Go to pseudo-G1 Cell Cycle Transitions
通过可逆的伪 G1 细胞周期转变对非分裂巨噬细胞进行 DNA 修复
基本信息
- 批准号:10247072
- 负责人:
- 金额:$ 45.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-02-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AgonistAutologousBase Excision RepairsBase PairingBiochemicalBiological AssayBlood Coagulation Factor VIICell CycleCellsChromatinComplementary DNAConflict (Psychology)DNADNA DamageDNA RepairDNA Repair EnzymesDNA biosynthesisDataDeaminationEnvironmentExcisionFractionationFrequenciesFunctional disorderGenomeGenomic DNAGenomicsGleanHIVHIV InfectionsHistone Deacetylase InhibitorHumanImmuneInfectionInflammatory ResponseInterphase CellInvestigationKnowledgeMEKsMapsMeasuresMetabolismMethodsMinorMutationNucleotidesPharmaceutical PreparationsPharmacologyPhenotypePhosphotransferasesPoly(ADP-ribose) PolymerasesPolymerasePopulationPredispositionProcessProvirusesReporterReporter GenesResolutionRestReverse TranscriptionRoleSerumSingle Strand Break RepairSiteThymidineTimeUracilViralViral ProteinsVirusVirus Diseasesbasefetal bovine seruminhibitor/antagonistmacrophageoxidationreceptorrepairedsequencing platformsmall moleculestemtooluracil-DNA glycosylasevascular inflammation
项目摘要
All faithful DNA repair processes require balanced dNTP pools. Conflicting with this requirement, non-dividing
macrophages have depleted canonical dNTPs and high levels of mutagenic dUTP, which is used as a defense
strategy against viral infection, but also poses a threat to the integrity of the host genome. This proposal will
explore how genome fidelity is maintained in macrophages that have a depleted and pro-mutagenic dNTP
pool. In addition, the knowledge gleaned from this study of macrophage DNA repair will be used to specifically
target HIV proviruses that contain high levels of dUMP arising from the presence of dUTP during reverse
transcription in macrophages. The basis of this proposal stems from our finding that non-dividing macrophages
(MDM) exist as two distinct populations with respect to their dUTP pools, uracil base excision repair (UBER)
status and susceptibility to HIV infection. The two populations were serendipitously detected because they
segregated as GFP- (high dUTP) and GFP+ (low dUTP) during infection with an HIV pseudo-viral construct
containing a GFP reporter gene. Further investigation characterized the GFP- population as resting (G0) and
the GFP+ population as pseudo-G1 (G1y), capable of low levels of DNA replication, but not cell division. Thus,
a mechanism to resolve the repair paradox is emerging where macrophages can be stimulated to reversibly
enter a G1y-state that has an environment conducive to high-fidelity DNA repair. In three specific aims, we
propose to: (i) Identify the serum factor that stimulates the G0àG1y transition in MDM. Using the retroviral
GFP reporter assay, we will use classic biochemical fractionation methods to isolate the serum small molecule
that stimulates the G0àG1y transition in MDM. (ii) Measure the repair capacities of homogenous G0 and G1y
MDM populations and the fate of genomic uracils after the G0àG1y transition. We will map uracilation in the
genomic DNA of G0 MDM by developing the first sequencing platform capable of distinguishing uracil from
thymidine in DNA with single nucleotide resolution (U2C-Seq). The fate of these genomic uracils (repair,
mutation, strand breaks) will be determined after transitioning to the G1y state. (iii) Pharmacologically destroy
uracilated HIV proviruses in G0 MDM to reduce virus-associated inflammatory responses. New data indicates
that HDAC inhibitors can induce chromatin opening and expose sequestered uracilated proviruses to uracil
excision. In a new HIV targeting strategy, we propose to block the post-excision stages of UBER using small
molecules. This strategy takes advantage of an HDAC inhibitor that exposes inaccessible uracils to excision
by uracil DNA glycosylase, and a second drug that inhibits repair of the resultant toxic abasic sites. The
decrease in functional virus will be correlated with reduced expression of viral proteins and a reduced
inflammatory response in MDM. This proposal will thus elucidate how macrophage immune cells repair
genomic DNA by reversibly transitioning between a repair deficient resting state and a repair competent active
state and the role of this transition in macrophage dysfunction and susceptibility to viral infection.
所有忠实的DNA修复过程都需要平衡的dNTP池。符合此要求的,非分割的
巨噬细胞已经耗尽了典型的dNTPs和高水平的诱变性dUTP,dUTP被用作防御
这不仅是对抗病毒感染的策略,而且对宿主基因组的完整性构成威胁。这项建议会
探索基因组保真度如何在具有耗尽和促突变dNTP的巨噬细胞中维持
池此外,从这项巨噬细胞DNA修复研究中获得的知识将用于专门研究
靶向HIV前病毒,其含有高水平的dUMP,所述dUMP由逆转录过程中dUTP的存在产生
在巨噬细胞中转录。这一建议的基础源于我们的发现,非分裂巨噬细胞
(MDM)存在两个不同的群体,就其dUTP池而言,尿嘧啶碱基切除修复(UBER)
艾滋病毒感染状况和易感性。这两个种群是偶然发现的,
在用HIV假病毒构建体感染期间分离为GFP-(高dUTP)和GFP+(低dUTP
含有GFP报告基因。进一步的研究将GFP-群体表征为静息(G0),
GFP+群体为假G1(G1 y),能够进行低水平的DNA复制,但不能进行细胞分裂。因此,在本发明中,
一种解决修复悖论的机制正在出现,其中巨噬细胞可以被刺激,
进入G1y状态,具有有利于高保真DNA修复的环境。在三个具体目标中,我们
建议:(i)确定刺激MDM中G0 <$G1 y转换的血清因子。利用逆转录病毒
GFP报告基因检测,我们将使用经典的生化分离方法来分离血清小分子
刺激MDM中的G0àG1y转变。(ii)测量同质G0和G1y的修复能力
MDM人群和基因组尿嘧啶在G0àG1y转换后的命运。我们将在地图上的尿嘧啶
通过开发第一个能够区分尿嘧啶和
单核苷酸解析(U2C-Seq)。这些基因组尿嘧啶的命运(修复,
突变,链断裂)将在转变为G1y状态后确定。(iii)药理学上破坏
尿嘧啶化的HIV前病毒在G0 MDM中减少病毒相关的炎症反应。新数据显示
HDAC抑制剂可以诱导染色质开放,并将隔离的尿嘧啶化前病毒暴露于尿嘧啶
切除在一项新的艾滋病毒靶向策略中,我们建议使用小分子药物阻断UBER的切除后阶段。
分子。该策略利用HDAC抑制剂使难以接近的尿嘧啶暴露于切除
通过尿嘧啶DNA糖基化酶,和第二种药物,抑制所产生的毒性脱碱基位点的修复。的
功能性病毒的减少将与病毒蛋白质表达的减少和病毒蛋白质表达的减少相关。
MDM中的炎症反应。因此,这项建议将阐明巨噬细胞免疫细胞如何修复
通过在修复缺陷的静息状态和修复活性之间可逆地转变,
状态以及这种转变在巨噬细胞功能障碍和对病毒感染的易感性中的作用。
项目成果
期刊论文数量(87)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Single-Stranded Nucleic Acids Bind to the Tetramer Interface of SAMHD1 and Prevent Formation of the Catalytic Homotetramer.
单链核酸与 SAMHD1 的四聚体界面结合并阻止催化同源四聚体的形成。
- DOI:10.1021/acs.biochem.6b00986
- 发表时间:2016-11-08
- 期刊:
- 影响因子:2.9
- 作者:Seamon KJ;Bumpus NN;Stivers JT
- 通讯作者:Stivers JT
Guanine-containing ssDNA and RNA induce dimeric and tetrameric structural forms of SAMHD1.
- DOI:10.1093/nar/gkad971
- 发表时间:2023-12-11
- 期刊:
- 影响因子:14.9
- 作者:Orris, Benjamin;Sung, Min Woo;Bhat, Shridhar;Xu, Yingrong;Huynh, Kevin W.;Han, Seungil;Johnson, Darren C.;Bosbach, Benedikt;Shields, David J.;Stivers, James T.
- 通讯作者:Stivers, James T.
Guanine-containing ssDNA and RNA induce dimeric and tetrameric SAMHD1 in cryo-EM and binding studies.
在冷冻电镜和结合研究中,含鸟嘌呤的 ssDNA 和 RNA 诱导二聚体和四聚体 SAMHD1。
- DOI:10.1101/2023.06.15.544806
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Orris,Benjamin;Sung,MinWoo;Bhat,Shridhar;Xu,Yingrong;Huynh,KevinW;Han,Seungil;Johnson,DarrenC;Bosbach,Benedikt;Shields,DavidJ;Stivers,JamesT
- 通讯作者:Stivers,JamesT
SAMHD1 is a single-stranded nucleic acid binding protein with no active site-associated nuclease activity.
- DOI:10.1093/nar/gkv633
- 发表时间:2015-07-27
- 期刊:
- 影响因子:14.9
- 作者:Seamon KJ;Sun Z;Shlyakhtenko LS;Lyubchenko YL;Stivers JT
- 通讯作者:Stivers JT
Small molecule versus DNA repair nanomachine.
小分子与 DNA 修复纳米机器。
- DOI:10.1038/nchembio0208-86
- 发表时间:2008
- 期刊:
- 影响因子:14.8
- 作者:Stivers,JamesT
- 通讯作者:Stivers,JamesT
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES T. STIVERS其他文献
JAMES T. STIVERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES T. STIVERS', 18)}}的其他基金
Discovery of Chemical Probes of SAMHD1 for Modulation of Cancer Therapy and the Immune System
发现用于调节癌症治疗和免疫系统的 SAMHD1 化学探针
- 批准号:
10163140 - 财政年份:2020
- 资助金额:
$ 45.85万 - 项目类别:
Discovery of Chemical Probes of SAMHD1 for Modulation of Cancer Therapy and the Immune System
发现用于调节癌症治疗和免疫系统的 SAMHD1 化学探针
- 批准号:
10396629 - 财政年份:2020
- 资助金额:
$ 45.85万 - 项目类别:
Discovery of Chemical Probes of SAMHD1 for Modulation of Cancer Therapy and the Immune System
发现用于调节癌症治疗和免疫系统的 SAMHD1 化学探针
- 批准号:
10650716 - 财政年份:2020
- 资助金额:
$ 45.85万 - 项目类别:
Fate of Invisible U/A Base Pairs Within HIV DNA in Myeloid Phagocytic Cells
骨髓吞噬细胞中 HIV DNA 中看不见的 U/A 碱基对的命运
- 批准号:
9138025 - 财政年份:2016
- 资助金额:
$ 45.85万 - 项目类别:
Persistence and Fate of Invisible U/A Pairs in HIV-1 Proviral DNA
HIV-1 前病毒 DNA 中隐形 U/A 对的持久性和命运
- 批准号:
8790165 - 财政年份:2014
- 资助金额:
$ 45.85万 - 项目类别:
Persistence and Fate of Invisible U/A Pairs in HIV-1 Proviral DNA
HIV-1 前病毒 DNA 中隐形 U/A 对的持久性和命运
- 批准号:
8910622 - 财政年份:2014
- 资助金额:
$ 45.85万 - 项目类别:
Purchase of a 600 MHz NMR Console and Probes
购买 600 MHz NMR 控制台和探头
- 批准号:
8051342 - 财政年份:2011
- 资助金额:
$ 45.85万 - 项目类别:
Fluorescence-Based Screen for Human DNA 5-Cytosine-methyltransferase 1
基于荧光的人类 DNA 5-胞嘧啶甲基转移酶 1 筛选
- 批准号:
8089372 - 财政年份:2010
- 资助金额:
$ 45.85万 - 项目类别:
Fluorescence-Based Screen for Human DNA 5-Cytosine-methyltransferase 1
基于荧光的人类 DNA 5-胞嘧啶甲基转移酶 1 筛选
- 批准号:
8010339 - 财政年份:2010
- 资助金额:
$ 45.85万 - 项目类别:
High Throughput Assay:Topoisomerase Enzyme Targets (RMI)
高通量检测:拓扑异构酶靶标 (RMI)
- 批准号:
7022489 - 财政年份:2005
- 资助金额:
$ 45.85万 - 项目类别:
相似海外基金
Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
- 批准号:
MR/Y019458/1 - 财政年份:2024
- 资助金额:
$ 45.85万 - 项目类别:
Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
- 批准号:
2897580 - 财政年份:2023
- 资助金额:
$ 45.85万 - 项目类别:
Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
- 批准号:
10658324 - 财政年份:2023
- 资助金额:
$ 45.85万 - 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
- 批准号:
10794761 - 财政年份:2023
- 资助金额:
$ 45.85万 - 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
- 批准号:
2304430 - 财政年份:2023
- 资助金额:
$ 45.85万 - 项目类别:
Cooperative Agreement
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
- 批准号:
23K15543 - 财政年份:2023
- 资助金额:
$ 45.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
- 批准号:
MR/X00466X/1 - 财政年份:2023
- 资助金额:
$ 45.85万 - 项目类别:
Fellowship
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
- 批准号:
10720234 - 财政年份:2023
- 资助金额:
$ 45.85万 - 项目类别:
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
- 批准号:
10976161 - 财政年份:2023
- 资助金额:
$ 45.85万 - 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
- 批准号:
10721983 - 财政年份:2023
- 资助金额:
$ 45.85万 - 项目类别:














{{item.name}}会员




